Valuation: Nuvectra Corporation

Market Cap 16.99L 14.72L 13.78L 12.58L 23.67L 16Cr 24.07L 1.62Cr 63.33L 8.11Cr 63.8L 62.41L 27Cr P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -5.35Cr -4.63Cr -4.34Cr -3.96Cr -7.45Cr -509.89Cr -7.57Cr -51Cr -20Cr -255.21Cr -20Cr -20Cr -851.43Cr EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 31/01/2019
Compliance Officer 51 01/01/2015
Director TitleAgeSince
Director/Board Member 67 01/03/2016
Director/Board Member 78 01/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 3L
+1.01%+4.04%-16.47%+4.19% 19TCr
+1.42%+5.20%-2.22%+8.66% 11TCr
+2.73%+9.01%+14.85%+78.19% 6.2TCr
-1.83%-0.46%+30.40%+59.78% 5.53TCr
+0.99%+6.64%-5.76%-35.74% 4.89TCr
+2.14%+2.98%+15.00%-19.84% 3.31TCr
+3.64%-16.65% - - 2.97TCr
-0.22%+0.75%+46.20%-10.99% 2.48TCr
+0.85%+13.55%-4.71%+22.40% 2.39TCr
Average +1.08%+2,939.82%+9.66%+13.33% 5.8TCr
Weighted average by Cap. +1.15%+2,682.94%+0.90%+14.15%

Financials

2017 2018
Net sales 3.18Cr 2.76Cr 2.58Cr 2.36Cr 4.43Cr 303.65Cr 4.51Cr 30Cr 12Cr 151.98Cr 12Cr 12Cr 507.05Cr 4.88Cr 4.23Cr 3.96Cr 3.61Cr 6.8Cr 465.74Cr 6.92Cr 46Cr 18Cr 233.12Cr 18Cr 18Cr 777.72Cr
Net income -4.46Cr -3.87Cr -3.62Cr -3.3Cr -6.21Cr -425.39Cr -6.32Cr -42Cr -17Cr -212.92Cr -17Cr -16Cr -710.34Cr -4.81Cr -4.17Cr -3.9Cr -3.56Cr -6.7Cr -459.07Cr -6.82Cr -46Cr -18Cr -229.78Cr -18Cr -18Cr -766.57Cr
Net Debt -14.9L -12.91L -12.09L -11.03L -20.76L -14Cr -21.1L -1.42Cr -55.53L -7.11Cr -55.95L -54.73L -24Cr -5.52Cr -4.78Cr -4.47Cr -4.08Cr -7.68Cr -526.09Cr -7.81Cr -52Cr -21Cr -263.32Cr -21Cr -20Cr -878.49Cr
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock